Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
New expert interviews from EMUC 2015, Barcelona, Spain – Hot topics and what’s new in advanced prostate cancer
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation
Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, et al.Future Oncol. 2015 Nov;11(22):3083-90.
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, et al.Target Oncol. 2015 Nov 6. [Epub ahead of print]
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, et al.Support Care Cancer. 2016 Jan;24(1):447-55.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al.N Engl J Med. 2015 Oct 29;373(18):1697-708.Topic: Pivotal trials
Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al.Prostate Cancer Prostatic Dis. 2015 Dec;18(4):333-7.
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.